quizartinib-sensitive PDGFR mutants [plasma membrane]

Stable Identifier
R-HSA-9674353
Type
Set [CandidateSet]
Species
Homo sapiens
Compartment
plasma membrane
Locations in the PathwayBrowser
Expand all
Literature References
PubMed ID Title Journal Year
16645167 Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

Lierman, E, Folens, C, Stover, EH, Mentens, N, Van Miegroet, H, Scheers, W, Boogaerts, M, Vandenberghe, P, Marynen, P, Cools, J

Blood 2006
31723821 FIP1L1-PDGFRα p.T674I-D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1-PDGFRα Positive Leukemia

Lierman, E, Smits, S, Appleby, N, Conneally, E, Michaux, L, Vandenberghe, P

Hemasphere 2019
Participants
members
candidates
Participant Of
hasMember
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer